HL7 Terminology (THO), published by HL7 International - Vocabulary Work Group. This guide is not an authorized publication; it is the continuous build for version 6.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/UTG/ and changes regularly. See the Directory of published versions
: ResearchStudyPhase - TTL Representation
Raw ttl | Download
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:CodeSystem ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "research-study-phase"] ; #
fhir:meta [
fhir:lastUpdated [ fhir:v "2020-04-09T21:10:28.568+00:00"^^xsd:dateTime ]
] ; #
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem research-study-phase</b></p><a name=\"research-study-phase\"> </a><a name=\"hcresearch-study-phase\"> </a><a name=\"research-study-phase-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Last updated: 2020-04-09 21:10:28+0000</p></div><p>This case-sensitive code system <code>http://terminology.hl7.org/CodeSystem/research-study-phase</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">n-a<a name=\"research-study-phase-n-a\"> </a></td><td>N/A</td><td>Trials without phases (for example, studies of devices or behavioral interventions).</td></tr><tr><td style=\"white-space:nowrap\">early-phase-1<a name=\"research-study-phase-early-phase-1\"> </a></td><td>Early Phase 1</td><td>Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.</td></tr><tr><td style=\"white-space:nowrap\">phase-1<a name=\"research-study-phase-phase-1\"> </a></td><td>Phase 1</td><td>Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.</td></tr><tr><td style=\"white-space:nowrap\">phase-1-phase-2<a name=\"research-study-phase-phase-1-phase-2\"> </a></td><td>Phase 1/Phase 2</td><td>Trials that are a combination of phases 1 and 2.</td></tr><tr><td style=\"white-space:nowrap\">phase-2<a name=\"research-study-phase-phase-2\"> </a></td><td>Phase 2</td><td>Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.</td></tr><tr><td style=\"white-space:nowrap\">phase-2-phase-3<a name=\"research-study-phase-phase-2-phase-3\"> </a></td><td>Phase 2/Phase 3</td><td>Trials that are a combination of phases 2 and 3.</td></tr><tr><td style=\"white-space:nowrap\">phase-3<a name=\"research-study-phase-phase-3\"> </a></td><td>Phase 3</td><td>Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.</td></tr><tr><td style=\"white-space:nowrap\">phase-4<a name=\"research-study-phase-phase-4\"> </a></td><td>Phase 4</td><td>Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.</td></tr></table></div>"
] ; #
fhir:extension ( [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg"^^xsd:anyURI ] ;
fhir:value [ fhir:v "brr" ]
] [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm"^^xsd:anyURI ] ;
fhir:value [ fhir:v "1"^^xsd:integer ]
] ) ; #
fhir:url [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-phase"^^xsd:anyURI] ; #
fhir:identifier ( [
fhir:system [ fhir:v "urn:ietf:rfc:3986"^^xsd:anyURI ] ;
fhir:value [ fhir:v "urn:oid:2.16.840.1.113883.4.642.1.1247" ]
] ) ; #
fhir:version [ fhir:v "1.0.0"] ; #
fhir:name [ fhir:v "ResearchStudyPhase"] ; #
fhir:title [ fhir:v "ResearchStudyPhase"] ; #
fhir:status [ fhir:v "draft"] ; #
fhir:experimental [ fhir:v "false"^^xsd:boolean] ; #
fhir:date [ fhir:v "2020-04-09T21:10:28+00:00"^^xsd:dateTime] ; #
fhir:publisher [ fhir:v "Health Level Seven International"] ; #
fhir:contact ( [
( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "http://hl7.org" ] ] [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "hq@HL7.org" ] ] )
] ) ; #
fhir:description [ fhir:v "Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation."] ; #
fhir:copyright [ fhir:v "This material derives from the HL7 Terminology (THO). THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html"] ; #
fhir:caseSensitive [ fhir:v "true"^^xsd:boolean] ; #
fhir:valueSet [
fhir:v "http://terminology.hl7.org/ValueSet/research-study-phase"^^xsd:anyURI ;
fhir:link <http://terminology.hl7.org/ValueSet/research-study-phase>
] ; #
fhir:content [ fhir:v "complete"] ; #
fhir:concept ( [
fhir:code [ fhir:v "n-a" ] ;
fhir:display [ fhir:v "N/A" ] ;
fhir:definition [ fhir:v "Trials without phases (for example, studies of devices or behavioral interventions)." ]
] [
fhir:code [ fhir:v "early-phase-1" ] ;
fhir:display [ fhir:v "Early Phase 1" ] ;
fhir:definition [ fhir:v "Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0." ]
] [
fhir:code [ fhir:v "phase-1" ] ;
fhir:display [ fhir:v "Phase 1" ] ;
fhir:definition [ fhir:v "Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients." ]
] [
fhir:code [ fhir:v "phase-1-phase-2" ] ;
fhir:display [ fhir:v "Phase 1/Phase 2" ] ;
fhir:definition [ fhir:v "Trials that are a combination of phases 1 and 2." ]
] [
fhir:code [ fhir:v "phase-2" ] ;
fhir:display [ fhir:v "Phase 2" ] ;
fhir:definition [ fhir:v "Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks." ]
] [
fhir:code [ fhir:v "phase-2-phase-3" ] ;
fhir:display [ fhir:v "Phase 2/Phase 3" ] ;
fhir:definition [ fhir:v "Trials that are a combination of phases 2 and 3." ]
] [
fhir:code [ fhir:v "phase-3" ] ;
fhir:display [ fhir:v "Phase 3" ] ;
fhir:definition [ fhir:v "Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug." ]
] [
fhir:code [ fhir:v "phase-4" ] ;
fhir:display [ fhir:v "Phase 4" ] ;
fhir:definition [ fhir:v "Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use." ]
] ) . #
|
|
Propose a change